Objective:

To investigate the prognostic value of diffuse splenic or bone marrow FDG uptake in lymphoma patients and evaluate its correlation with systemic inflammatory markers, emphasizing its clinical significance.

Key Findings:

• Diffuse FDG uptake in the spleen and bone marrow may indicate systemic inflammation and correlate with poor survival outcomes, suggesting a need for further investigation.
• Elevated inflammatory markers such as LDH and D-dimer were associated with aggressive lymphoma behavior, highlighting their potential as prognostic indicators.
• The study suggests that PET/CT metrics can refine prognostic stratification in lymphoma patients, potentially guiding treatment decisions.

Interpretation:

Diffuse hypermetabolism in the spleen and bone marrow reflects heightened systemic inflammatory activity, potentially serving as an independent prognostic indicator for lymphoma progression and survival, with implications for clinical practice.

Limitations:

• The study is retrospective and conducted at a single center, which may limit generalizability.
• Exclusion criteria may have led to a selection bias, affecting the representativeness of the sample, and potential biases in data collection methods should be acknowledged.

Conclusion:

Integrating PET/CT-derived metrics with inflammatory markers could enhance prognostic assessment and guide individualized treatment strategies in lymphoma patients, ultimately improving patient outcomes.